

Additional file 3: Continuation rates (percent remaining in the study) over 12 weeks because of adverse event in trials lasting 4-12 weeks

All trials (osteoarthritis, rheumatoid arthritis, chronic low back pain, ankylosing spondylitis)

Week	Placebo	Etoricoxib				Diclofenac 150 mg	Naproxen 1000 mg	Ibuprofen 2400 mg	Celecoxib 200/400 mg
		30 mg	60 mg	90 mg	120 mg				
Number	2336	1015	1120	1238	664		1113	649	488
0	100	100	100	100	100		100	100	100
1	99	99	99	100	99		99	99	100
2	98	99	98	98	98		98	98	99
3	97	98	96	98	98		98	95	98
4	97	98	96	97	97		97	95	98
5	96	98	96	96	96		96	94	97
6	95	98	95	96	95		95	94	97
8	94	97	94	95	94		95	92	96
12	93	96	92	94	93		93	90	96

OA trials only

Week	Placebo	Etoricoxib				Diclofenac 150 mg	Naproxen 1000 mg	Ibuprofen 2400 mg	Celecoxib 200/400 mg
		30 mg	60 mg	90 mg	120 mg				
Number	974	1015	590				439	423	488
0	100	100	100	100	100		100	100	100
1	99	99	100				99	99	100
2	98	99	99				98	97	99
3	96	98	98				97	94	98
4	96	98	98				96	93	98
5	95	98	98				95	92	97
6	95	98	97				93	92	97
8	94	97	95				93	91	96
12	93	96	93				90	89	96

RA trials only

Week	Placebo	Etoricoxib				Diclofenac 150 mg	Naproxen 1000 mg	Ibuprofen 2400 mg	Celecoxib 200/400 mg
		30 mg	60 mg	90 mg	120 mg				
Number	1050			810	371		595		
0	100	100	100	100	100	100	100	100	100
1	100			100	99		99		
2	99			98	98		98		
3	98			98	97		98		
4	98			98	97		97		
5	97			98	96		96		
6	96			98	95		96		
8	94			98	95		96		
12	94			96	94		95		